{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-004458","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.758687+00:00","generated_at":"2026-06-17T19:07:41.652387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics reports FY2022 net loss $17.6M; cash $22.1M; GT-02287 on track for Phase 1 in H2 2023","bullets":["Net loss $17.6M ($1.48/share) vs $13.9M ($1.37) in 2021; R&D spend $8.4M, G&A $9.5M.","Cash and marketable securities $22.1M as of Dec 31, 2022; runway expected into Q2 2024.","GT-02287 IND-enabling studies completed H1 2023; Phase 1 dossier submission by mid-2023; Australian trial in H2 2023.","Awarded €1.2M non-dilutive grant for Alpha-1 Antitrypsin Deficiency research program."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-004458","json":"https://secwatch.observer/filing/0001558370-23-004458.json","markdown":"https://secwatch.observer/filing/0001558370-23-004458.md","text":"https://secwatch.observer/filing/0001558370-23-004458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/0001558370-23-004458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/ganx-20230323x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:07:41.652387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b87606e4389485eea5f42b58a62d9e89b42f004c","claim":"Gain Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $140,108, net income $17.59 million, EPS $1.48.","evidence_excerpt":"(audited) ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Revenues: ​ ​ ​ Collaboration revenues ​ $ 132,640 ​ $ 133,928 Other income ​ ​ 7,468 ​ 31,066 Total revenues ​ ​ 140,108 ​ ​ 164,994 ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ Research and development ​ (8,377,290) ​ (7,164,229) General and administrative ​ (9,539,863) ​ (6,826,938) Total operating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/0001558370-23-004458-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$140,108"},{"label":"Net income","value":"$17.59 million"},{"label":"EPS","value":"$1.48"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}